Loading organizations...
Ignis Therapeutics is a biotechnology company based in Shanghai, China, dedicated to developing innovative therapies for central nervous system (CNS) diseases. The company has successfully raised between $180 million and $185 million in Series A funding, attracting prominent investors such as 6 Dimensions Capital, SK Biopharmaceuticals, Mubadala, Goldman Sachs, HBM Healthcare Investments, KB Investment, and WTT. With over 100 employees and managing more than 20 pipeline projects, Ignis Therapeutics is committed to transforming cutting-edge science into medical solutions for patients. Its focus areas encompass debilitating conditions like epilepsy, excessive daytime sleepiness, insomnia, Parkinson's disease, and migraine. Led by Chairman Leon Chen and CEO Eileen Long, the company was established at the end of 2020 to address significant unmet medical needs.
Ignis Therapeutics has raised $180.0M across 1 funding round.
Ignis Therapeutics has raised $180.0M in total across 1 funding round.
Ignis Therapeutics has raised $180.0M in total across 1 funding round.
Ignis Therapeutics's investors include 6 Dimensions Capital, ARCH Venture Partners, Northpond Ventures.
Ignis Therapeutics has raised $180.0M across 1 funding round. Most recently, it raised $180.0M Series A in November 2021.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Nov 1, 2021 | $180M Series A | — | 6 Dimensions Capital, ARCH Venture Partners, Northpond Ventures | Announced |
Ignis Therapeutics is a Shanghai‑based biotechnology company focused on developing and commercializing therapies for central nervous system (CNS) disorders; it was founded around 2020 and raised a large Series A (~$180–185M) to build a pipeline that includes licensed FDA‑approved molecules plus in‑house discovery programs[1][2][4][3].
High‑Level Overview
Origin Story
Core Differentiators
Role in the Broader Tech / Biopharma Landscape
Quick Take & Future Outlook
If you want, I can: